Pharmaceutical manufacturers have ramped up production of chloroquine amid hopes that the antimalarial drug will prove effective against COVID-19.
By Kelly ServickScience’s COVID-19 reporting is supported by the Pulitzer Center.On 19 March, as much of the United States shut down to contain the new coronavirus, genetic cardiologist Michael Ackerman and his wife drove 7.5 hours to retrieve their son from college.
On the radio, they heard medical experts discussing chloroquine and hydroxychloroquine, two antimalarial drugs that President Trump had just touted at a press briefing, despite no conclusive evidence that they can treat COVID-19.